These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1328 related items for PubMed ID: 18583022

  • 21. Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study).
    Choo MS, Doo CK, Lee KS.
    Int J Clin Pract; 2008 Feb; 62(2):191-6. PubMed ID: 18067558
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y, Zhao XF, Li HZ, Wang W, Zhang Y, Xiao H, Zhang X.
    Chin Med J (Engl); 2007 Mar 05; 120(5):370-4. PubMed ID: 17376305
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE, Morrow JD, Kraus SR, Creanga D, Bavendam T.
    Neurourol Urodyn; 2012 Nov 05; 31(8):1258-65. PubMed ID: 22907761
    [Abstract] [Full Text] [Related]

  • 24. Editorial comment on: Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
    Porru D.
    Eur Urol; 2009 Feb 05; 55(2):480. PubMed ID: 18583021
    [No Abstract] [Full Text] [Related]

  • 25. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia.
    Kaplan SA, Roehrborn CG, Dmochowski R, Rovner ES, Wang JT, Guan Z.
    Urology; 2006 Aug 05; 68(2):328-32. PubMed ID: 16904446
    [Abstract] [Full Text] [Related]

  • 26. Editorial comment on: Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
    Wyndaele JJ.
    Eur Urol; 2009 Feb 05; 55(2):481. PubMed ID: 18583023
    [No Abstract] [Full Text] [Related]

  • 27. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia.
    Nitti VW, Dmochowski R, Appell RA, Wang JT, Bavendam T, Guan Z, 037 Study Group.
    BJU Int; 2006 Jun 05; 97(6):1262-6. PubMed ID: 16686723
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder.
    Dmochowski R, Abrams P, Marschall-Kehrel D, Wang JT, Guan Z.
    Eur Urol; 2007 Apr 05; 51(4):1054-64; discussion 1064. PubMed ID: 17097217
    [Abstract] [Full Text] [Related]

  • 29. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG, Siami P, Barkin J, Damião R, Becher E, Miñana B, Mirone V, Castro R, Wilson T, Montorsi F, CombAT Study Group.
    Eur Urol; 2009 Feb 05; 55(2):461-71. PubMed ID: 19013011
    [Abstract] [Full Text] [Related]

  • 30. Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial.
    Elinoff V, Bavendam T, Glasser DB, Carlsson M, Eyland N, Roberts R.
    Int J Clin Pract; 2006 Jun 05; 60(6):745-51. PubMed ID: 16805763
    [Abstract] [Full Text] [Related]

  • 31. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
    Malone-Lee JG, Al-Buheissi S.
    BJU Int; 2009 Apr 05; 103(7):931-7. PubMed ID: 19281469
    [Abstract] [Full Text] [Related]

  • 32. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.
    Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W.
    J Urol; 2009 Dec 05; 182(6):2825-30. PubMed ID: 19837435
    [Abstract] [Full Text] [Related]

  • 33. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
    Coyne KS, Elinoff V, Gordon DA, Deng DY, Brodsky M, Glasser DB, Jumadilova Z, Carlsson M.
    Int J Clin Pract; 2008 Jun 05; 62(6):925-31. PubMed ID: 18479285
    [Abstract] [Full Text] [Related]

  • 34. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder.
    Dmochowski R, Kreder K, MacDiarmid S, Carlsson M, Guan Z.
    BJU Int; 2007 Jul 05; 100(1):107-10. PubMed ID: 17552957
    [Abstract] [Full Text] [Related]

  • 35. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients.
    Takei M, Homma Y, JAPANESE TOLTERODINE STUDY GROUP.
    Int J Urol; 2005 May 05; 12(5):456-64. PubMed ID: 15948744
    [Abstract] [Full Text] [Related]

  • 36. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial.
    Peters KM, Macdiarmid SA, Wooldridge LS, Leong FC, Shobeiri SA, Rovner ES, Siegel SW, Tate SB, Jarnagin BK, Rosenblatt PL, Feagins BA.
    J Urol; 2009 Sep 05; 182(3):1055-61. PubMed ID: 19616802
    [Abstract] [Full Text] [Related]

  • 37. Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration.
    Wein AJ, Khullar V, Wang JT, Guan Z.
    BJU Int; 2007 Feb 05; 99(2):360-3. PubMed ID: 17155987
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentration.
    Chapple CR, Herschorn S, Abrams P, Wang JT, Brodsky M, Guan Z.
    BJU Int; 2010 Nov 05; 106(9):1332-8. PubMed ID: 20497416
    [Abstract] [Full Text] [Related]

  • 39. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder.
    Kelleher CJ, Reese PR, Pleil AM, Okano GJ.
    Am J Manag Care; 2002 Dec 05; 8(19 Suppl):S608-15. PubMed ID: 12516955
    [Abstract] [Full Text] [Related]

  • 40. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder.
    Chapple C, Van Kerrebroeck P, Tubaro A, Haag-Molkenteller C, Forst HT, Massow U, Wang J, Brodsky M.
    Eur Urol; 2007 Oct 05; 52(4):1204-12. PubMed ID: 17651893
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 67.